{"id":"NCT03406507","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria","officialTitle":"A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-22","primaryCompletion":"2020-03-25","completion":"2022-08-25","firstPosted":"2018-01-23","resultsPosted":"2022-05-09","lastUpdate":"2023-03-27"},"enrollment":13,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","Ultomiris"]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).","primaryOutcome":{"measure":"Maximum Observed Serum Concentration (Cmax) Of Ravulizumab","timeFrame":"Week 1 (Day 1), Week 2 (Day 15), Week 10 (Day 71), and Week 18 (Day 127)","effectByArm":[{"arm":"Treatment Na√Øve","deltaMin":725.4,"sd":93.73},{"arm":"Eculizumab Experienced","deltaMin":884.63,"sd":170.842}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["United States","France","Netherlands","Norway","Russia","United Kingdom"]},"refs":{"pmids":["38551806"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":5},"commonTop":["Abdominal pain","Nausea","Nasopharyngitis","Headache","Abdominal pain upper"]}}